Turning Point Therapeutics to be acquired by Bristol Myers Squibb for $4.1B

Notable

Jun 3

Written By Frances Benson

https://www.tptherapeutics.com/news-releases/news-release-details/bristol-myers-squibb-acquire-turning-point-therapeutics-leading

2022

Frances Benson

Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial

Odyssey Therapeutics appoints Darryl Patrick as Executive Vice President of Non-Clinical Development